Status:
UNKNOWN
Investigation of Gene Mutations in Patients With Triple-negative and Patients With HER2+ Breast Cancer Adenocarcinoma
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The present study is a transnational study in patients with high risk recurrent breast cancer who receive adjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel or paclitaxel...
Detailed Description
This will be a retrospective analysis of patients with histologically confirmed triple-negative or HER2+ operable breast cancer (with high risk of recurrence) who are treated at Hellenic Cooperative O...
Eligibility Criteria
Inclusion
- 18 years or older
- Αny menopausal status is allowed
- triple-negative breast cancer
- HER2+ breast adenocarcinoma
- tumor size \<= 5 cm
- presence of operable axillary lymph nodes or the presence of clinicopathological parameters indicating an intermediate or high risk of recurrence without the presence of infiltrated lymph nodes
- Performance status (PS) = 0 or 1
- adequate bone marrow function , heart, liver and kidney
- no other history of previous neoplasm or other serious illness
Exclusion
Key Trial Info
Start Date :
April 18 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04365790
Start Date
April 18 2013
End Date
September 1 2023
Last Update
March 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
George Fountzilas
Athens, Greece